Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5.
Yuan He,Djoke Hendriks,Robert van Ginkel,Douwe Samplonius,Edwin Bremer,Wijnand Helfrich
DOI: https://doi.org/10.1016/j.jid.2015.11.009
2015-01-01
Abstract:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an immune effector protein that induces apoptosis in virus-infected and cancer cells by activating death receptor-4 (DR4) and/or death receptor-5 (DR5) without deleterious activity toward DR4/DR5-expressing normal cells (Ashkenazi et al., 2008Ashkenazi A. Holland P. Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).J Clin Oncol. 2008; 26: 3621-3630Crossref PubMed Scopus (355) Google Scholar). Consequently, DR4/DR5 agonists are promising anticancer agents. Treatment with “first-generation” DR4/DR5-targeted therapeutics, such as recombinant human soluble tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) and agonistic DR4/DR5 antibodies, was well tolerated but had disappointing clinical activity (Ashkenazi, 2015Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions.J Clin Invest. 2015; 125: 487-489Crossref PubMed Scopus (177) Google Scholar). For instance, in a phase I dose-escalation study in patients with relapsed or refractory carcinoma, the DR5-agonistic antibody tigatuzumab only induced stable disease (Forero-Torres et al., 2010Forero-Torres A. Shaw J. Wood T. Posey J. Carlisle R. Copigneaux C. et al.Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).Cancer Biother Radiopharm. 2010; 25: 13-19Crossref PubMed Scopus (119) Google Scholar). In a phase II trial in non-small cell lung cancer patients, combined treatment with rhTRAIL and chemotherapy had no added benefit (Soria et al., 2011Soria J.C. Mark Z. Zatloukal P. Szima B. Albert I. Juhász E. et al.Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.J Clin Oncol. 2011; 29: 4442-4451Crossref PubMed Scopus (193) Google Scholar). However, advances in our understanding of DR signaling revealed that first-generation DR4/DR5 agonists do not fully exploit the unique signaling characteristics of TRAIL receptor-mediated cancer cell death (Ashkenazi, 2015Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions.J Clin Invest. 2015; 125: 487-489Crossref PubMed Scopus (177) Google Scholar, de Bruyn et al., 2013de Bruyn M. Bremer E. Helfrich W. Antibody-based fusion proteins to target death receptors in cancer.Cancer Lett. 2013; 332: 175-183Crossref PubMed Scopus (48) Google Scholar). Specifically, rhTRAIL and conventional agonistic DR4/5 antibodies have no tumor-selective binding activity, whereas TRAIL receptors are ubiquitously expressed on normal tissue (Spierings et al., 2004Spierings D.C. de Vries E.G. Vellenga E. van den Heuvel F.A. Koornstra J.J. Wesseling J. et al.Tissue distribution of the death ligand TRAIL and its receptors.J Histochem Cytochem. 2004; 52: 821-831Crossref PubMed Scopus (143) Google Scholar). Consequently, their efficacy may be hampered by a target antigen sink of normal healthy cells. Moreover, DR4 and DR5 have distinct cross-linking requirements for the induction of apoptosis. DR4 is activated upon binding of rhTRAIL (or conventional DR4 antibodies), whereas apoptotic DR signaling requires membrane-bound TRAIL or secondarily cross-linked rhTRAIL (de Bruyn et al., 2010de Bruyn M. Rybczynska A.A. Wei Y. Schwenkert M. Fey G.H. Dierckx R.A. et al.Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.Mol Cancer. 2010; 9: 301Crossref PubMed Scopus (56) Google Scholar, Nair et al., 2015Nair P.M. Flores H. Gogineni A. Marsters S. Lawrence D.A. Kelley R.F. et al.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.Proc Natl Acad Sci U S A. 2015; 112: 5679-5684Crossref PubMed Scopus (61) Google Scholar). Similarly, to gain therapeutic activity, agonistic DR5 antibodies such as tigatuzumab appear to require cross-linking by Fcγ receptors on myeloid effector cells (Bruhns et al., 2009Bruhns P. Iannascoli B. England P. Mancardi D.A. Fernandez N. Jorieux S. et al.Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.Blood. 2009; 113: 3716-3725Crossref PubMed Scopus (981) Google Scholar, Li and Ravetch, 2013Li F. Ravetch J.V. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo.Proc Natl Acad Sci U S A. 2013; 110: 19501-19506Crossref PubMed Scopus (77) Google Scholar). Here, we present a strategy for melanoma-directed activation of apoptosis using a bispecific antibody with specificity for the melanoma-associated chondroitin sulfate proteoglycan (MCSP) and DR5. In brief, a bispecific tetravalent antibody, designated MCSPxDR5, was constructed comprising the binding domains of tigatuzumab and high-affinity anti-MCSP mAb 9.2.27 complemented with a human IgG1 Fc domain (Figure 1a). MCSP is highly overexpressed on the cell surface of >90% of melanomas and is a well-established target for melanoma immunotherapy because its expression in normal tissues is mainly restricted to melanocytes (Campoli et al., 2004Campoli M.R. Chang C.C. Kageshita T. Wang X. McCarthy J.B. Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance.Crit Rev Immunol. 2004; 24: 267-296Crossref PubMed Scopus (150) Google Scholar). Correspondingly, MCSPxDR5 strongly bound to MCSP+ SK-MEL-28 melanoma cells (Figure 1b, red line vs. black line) and minimally to MCSP–/DR5+ DLD-1 carcinoma cells (Figure 1c, red line vs. black line). Binding of MCSPxDR5 to SK-MEL-28 was abrogated by preincubation with MAb 9.2.27 (Figure 1b, blue line). Thus, MCSPxDR5 binds to cell surface-expressed DR5, but binding to melanoma cells as such is dominated by its high-affinity for MCSP. Treatment with MCSPxDR5 for 40 minutes at 4 °C followed by removal of unbound antibody selectively triggered apoptosis in MCSP+ and DR5+ melanoma cell lines MM-RU, M14.MCSP, and A375M but not in MCSP– HCT116 carcinoma cells (Figure 1d). Of note, treatment in the continued presence of MCSPxDR5 also induced apoptosis in DLD-1 cells, although to a markedly lower extent (Figure 1e). Furthermore, MCSPxDR5 treatment strongly reduced tumor cell viability (Figure 1f) and anchorage-independent colony-forming capacity of melanoma cells (Figure 1g). Any residual colonies formed during treatment were reduced in size >90% (Figure 1h). Importantly, primary tumor cells isolated from melanoma patients proved sensitive to MCSPxDR5 treatment, with a >40% increase in apoptosis compared to medium control (Figure 1i). Because therapeutic activity of agonistic DR5 antibodies such as tigatuzumab appears to require cross-linking by Fcγ receptors of myeloid effector cells, we evaluated whether MCSP-directed activity of MCSPxDR5 was also enhanced by cross-linking of its Fc domain. We exploited MCSP–/DR5+ Jurkat cells as indicator cells that are sensitive only to secondary cross-linked MCSPxDR5. As expected, treatment of Jurkat cells with MCSPxDR5 alone did not induce apoptosis (Figure 2a). However, cross-linking of MCSPxDR5 using an anti-human Fc antibody triggered apoptosis >95% (Figure 2a). This enhancement was already apparent at low MCSPxDR5 doses down to 5 ng/ml (Figure 2a). Secondary cross-linking of MCSPxDR5 also increased its agonistic activity toward both melanoma cells (Figure 2b) and primary patient-derived melanoma cells, with a mean increase in apoptosis from 48% to 70% (Figure 2c). MCSPxDR5 activity was abrogated by cotreatment with recombinant DR5-Fc or pan-caspase inhibitor zVADfmk as illustrated for the melanoma cell line MM-RU (Figure 2d). Moreover, RNA silencing of DR5 in A375M cells strongly reduced the apoptotic activity of both MCSPxDR5 and the DR5-agonistic antibody HGS-ETR2 (Figure 2e and f), whereas treatment with mAb 9.9.27 alone did not induce apoptosis (Figure 2d). Together, these data demonstrate that MCSPxDR5 induces apoptosis through DR5 signaling. Next, the potential therapeutic effect of Fc cross-linking by surface-expressed Fc receptors was evaluated using HEK293.CD64 cells ectopically expressing the high-affinity Fcγ receptor. HEK293 cells are resistant to TRAIL receptor–mediated apoptosis and lack cytolytic or phagocytic activity (data not shown). In the presence of parental HEK-293 cells and at suboptimal concentrations of MCSPxDR5 (50 ng/ml), only ∼25% apoptosis was observed in MM-RU melanoma cells (Figure 2g). However, in the presence of HEK293.CD64 cells, MCSPxDR5 induced apoptosis in up to 60% of MM-RU cells (Figure 2g). Fc receptor–mediated cross-linking of MCSPxDR5-IgG4, an isotype devoid of antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity, yielded similar results (Figure 2g). Of note, Fc receptor cross-linking also to some extent induced MCSP-independent DR5 signaling in MCSP– M14 cells (Figure 2g). Nevertheless, Fc receptor–mediated cross-linking on MCSP+ cells was abrogated in the presence of mAb 9.9.27 (Figure 2h), indicating that MCSP binding of MCSPxDR5 is pivotal for optimal Fc cross-linking. In analogous mixed culture experiments using freshly isolated leukocytes, MCSPxDR5 also induced a dose-dependent decrease in tumor cell viability down to 20% at an effector cell: target cell ratio of 5:1 (Figure 2i). Together, these data indicate that MCSPxDR5 can trigger antitumor antibody-dependent cell-mediated cytotoxic (ADCC) activity in Fc receptor–positive immune effector cells, which may enhance its in vivo efficacy. In conclusion, we present a DR5 agonist-based bispecific antibody in which high-affinity binding to MCSP leads to melanoma cell-localized activation of DR5. Antitumor activity of MCSPxDR5 was enhanced by Fc receptor–mediated cross-linking by myeloid immune effector cells. This bispecific antibody approach may provide a new avenue to unlock the therapeutic potential of DR5-targeted cancer therapy. The authors state no conflict of interest. This work was supported by grants from the Dutch Cancer Society (RUG2011-5206, RUG2013-6209, RUG2014-6986) and the China Scholarship Council. Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant MelanomaJournal of Investigative DermatologyVol. 136Issue 2PreviewDiscovery of oncogene and immune checkpoint targeting has transformed melanoma therapy in the last 5 years. However, treatment of primary or secondary drug-resistant melanoma remains a challenge. Agents designed to activate the cell death machinery directly, for example by activating the death receptors expressed by melanoma cells, could break drug resistance, and they may achieve long-lasting therapeutic success. He et al. report their studies of an MCSPxDR5 bispecific, tetravalent antibody that can simultaneously target death receptor 5 (DR5, TRAIL-R2) and melanoma-associated chondroitin sulfate proteoglycan (MCSP). Full-Text PDF Open Archive